Michael Avraam, head of solutions engineering at ChargePoint Technology explains how containment valves and wireless monitoring mitigate risk during HPAPI manufacture.
Cocktails
Analysts estimate that the oral solid dosage (OSD) market will reach the trillion-dollar mark in the next decade, having rocketed to nearly US $21.5bn in 2018 [1]. Similarly, the highly potent API (HPAPI) market is expected to rise, reaching $26bn by 2023.[2]
Further knowledge of existing compounds is one of the forces behind this momentum – as new toxicity data is produced, some of these compounds are reclassified as HPAPIs. In addition, there is increasing demand for more effective, better-targeted medications; hence manufacturers are handling more and more HPAPIs. However, containment strategies are required to protect both operator safety and the drug product itself.